May 23 |
89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
|
May 22 |
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
|
May 14 |
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
|
May 10 |
89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials
|
May 9 |
89bio GAAP EPS of -$0.54 misses by $0.07
|
May 9 |
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
May 9 |
‘Jump on the Bandwagon,’ Says Bank of America About These 2 Stock Picks
|
May 8 |
89bio to Participate in the BofA Securities 2024 Health Care Conference
|
May 2 |
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
|
Apr 17 |
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
|